Magnolol's Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma.

Autor:	Tseng CF; Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan, R.O.C.; Department of Dentistry, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C., Chen HM; Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan, R.O.C.; Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan, R.O.C.; Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Department of Dentistry, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C., Liao TL; Department of Biomedical Imaging and Radiological Science, National Yang-Ming Chiao Tung University, Taipei, Taiwan, R.O.C.; Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C., Hsu FT; Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, R.O.C., Yeh CJ; Department of Molecular Biology and Cell Research, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; joe.0221@gmail.com., Chen WT; Department of Psychiatry, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; wt820368@yahoo.com.tw.; Department of Physical Therapy, Shu-Zen Junior College of Medicine and Management, Kaohsiung, Taiwan, R.O.C., Kok SH; Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan, R.O.C.; shkok@ntu.edu.tw.; Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Department of Dentistry, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2024 Sep-Oct; Vol. 38 (5), pp. 2152-2164.
DOI:	10.21873/invivo.13678
Abstrakt:	Background/aim: Oral squamous cell carcinoma (OSCC) presents a significant health challenge, requiring effective treatments. Magnolol, a compound with potential anticancer properties, warrants investigation in OSCC treatment. Here, we aimed to assess the efficacy of magnolol in inhibiting progression of OSCC and to explore the underlying mechanisms of its action. Materials and Methods: We evaluated the effect of magnolol on tumor progression using the MOC1-bearing orthotopic model. We examined its impact on pathology and toxicity through hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC), and biochemical analysis. We also investigated the immunoregulatory effects of magnolol in the MOC1-bearing model using flow cytometry. Results: At high doses, magnolol significantly reduced tumor volume (p<0.0001 for comparisons between treated with magnolol and untreated groups) and weight loss by 70% in vivo. It also induced caspase-dependent apoptosis, evidenced by 2.42-, 2-, and 2.2-fold increases in the expression of caspase-3, -8, and -9, respectively, in mouse tumors treated with high 60 mg/kg of magnolol compared to untreated (p<0.0001 for all comparisons). Magnolol demonstrated no toxicity, maintaining body weight and normal biochemical parameters, including liver and kidney function. Pathological evaluations showed no adverse effects on organs in all treatment groups. Moreover, high doses of magnolol enhanced natural killer cells (by 3%), dendritic cells (20-25%), and cytotoxic T cells (20-40%) while reducing myeloid-derived suppressor cells and regulatory T cells by 1.5 times. Conclusion: Magnolol demonstrates potential as a therapeutic agent for OSCC, offering antitumor efficacy and immunomodulatory benefits. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu